What did @weightdoc actually say?
The core claim here is straightforward: GLP-1 medications do not have a proven link to increased blood clot risk, and some evidence suggests they might actually lower it. The creator frames this as a correction to scaremongering from other physicians who aren't familiar with GLP-1 prescribing. They argue that GLP-1s reduce weight, blood pressure, and inflammation, all of which are established contributors to clot risk, and that the fear-based pushback disproportionately targets patients using these drugs for obesity rather than diabetes. That last point about weight bias is pointed and worth sitting with.
The creator is a self-described primary care physician, and the clinical frustration comes through clearly. They aren't making a fringe argument. But "large studies do not show any definite increased risk" is doing some work here, so let's look at what those studies actually say.
Does the science back this up?
Mostly, yes. The evidence on GLP-1s and venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, leans in the direction the creator describes. A 2023 observational study by Sodhi et al. published in JAMA Internal Medicine found no significant increased risk of VTE in patients using semaglutide compared to other diabetes or obesity medications. The cardiovascular outcome trials are also telling: LEADER (liraglutide, Marso et al., 2016, NEJM) and SUSTAIN-6 (semaglutide, Marso et al., 2016, NEJM) showed reductions in major adverse cardiovascular events, not increases. SURMOUNT-1 (tirzepatide, Jastreboff et al., 2022, NEJM) showed similar cardiovascular-friendly trends.
That said, "may even lower risk" is a softer claim than it sounds. The mechanistic argument, that weight loss plus reduced inflammation plus lower blood pressure equals lower clot risk, is plausible and supported by general cardiovascular literature, but direct evidence that GLP-1s lower VTE rates specifically is less definitive than the cardiovascular mortality data.
What did they get wrong (or right)?
They got the big picture right. No major regulatory agency, including the FDA or EMA, lists increased VTE risk as a recognized adverse effect of approved GLP-1 receptor agonists. The creator is correct that physicians who are not familiar with this drug class may be importing fears from older obesity medications, some of which did carry clot risks, onto a mechanistically different class of drugs.
Where the video slightly overshoots is in the phrase "may even lower risk." This is plausible and mechanistically reasonable, but it is not yet established by prospective, controlled data specifically designed to test VTE outcomes. Saying "may lower" is fine. Saying it with the confidence implied here could leave patients expecting a protective effect that hasn't been formally proven. The weight bias observation, by contrast, is sharp and well-supported. Studies on clinical decision-making consistently show that patients with obesity receive differential treatment recommendations compared to metabolically similar patients without obesity. That part deserves more attention than it usually gets.
What should you actually know?
If you are on a GLP-1 medication and a provider tells you these drugs cause blood clots, ask them to show you the evidence. As of 2024, it does not exist in any credible, replicated form. The cardiovascular safety profile of semaglutide and tirzepatide is among the most well-documented of any weight management medication in history, with multiple large randomized controlled trials backing it up.
That doesn't mean GLP-1s are risk-free. Gastrointestinal side effects are real and common. There are ongoing investigations into thyroid C-cell tumors based on rodent data, and gastroparesis risk is being actively studied. The point is that blood clot risk, as of current evidence, is not a legitimate reason to avoid these medications. If you are weighing risks and benefits with your prescribing physician, VTE should not be on the fear list unless you have independent clotting risk factors that would apply regardless of medication choice.